|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease.
|
31145704 |
2019 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
FGF23 has also been shown to independently predict progression of renal disease, however, whether FGF23 and FGFR4 also contribute to CKD remains unknown.
|
31575945 |
2019 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Objective Non-alcoholic fatty liver disease, steatohepatitis and nephropathy are considered among the most important complications of diabetes mellitus (DM), which recently increased due to increased frequency of DM and the prolonged life span of diabetic patients The aim of the present study was to reveal the possible effect of hesperidin (HP) on alpha-klotho (α-KL)/ fibroblast growth factor-23 (FGF-23) pathway in rats with diabetes induced by streptozotocin (STZ).
|
30551370 |
2019 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
αKlotho-FGF23 interactions and their role in kidney disease: a molecular insight.
|
31350618 |
2019 |
|
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Patients with kidney disease have increased circulating levels of FGF23 and in other patient populations and in healthy individuals, FGF23 levels also rise following an increase in dietary phosphate intake.
|
30514976 |
2019 |
|
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of current study is investigation of theimpact of serum FGF23 levels on blood pressure of patients withend-stage renal disease (ESRD) undergoing hemodialysis.
|
31422393 |
2019 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, a higher concentration of FGF-23 reduced the odds of early nephropathy in patients with T2DM.
|
30718148 |
2018 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk.
|
29735309 |
2018 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This may explain, or at least contribute to, the decrease in Klotho and promote fibroblast growth factor 23 resistance in early CKD categories, as observed in preclinical and clinical proteinuric kidney disease.
|
29425318 |
2018 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies showed that circulating fibroblast growth factor-23 (FGF23) is a new biomarker linked to cardiovascular and kidney diseases.
|
27427468 |
2017 |
|
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Circulating levels of fibroblast growth factor 23 (FGF23) increase during the early stages of kidney disease, but the underlying mechanism remains incompletely characterized.
|
27535551 |
2017 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor 23 (FGF23) is a novel biomarker positively associated with left ventricular hypertrophy in adults with and without kidney disease.
|
28456498 |
2017 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
|
28705885 |
2017 |
|
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Advanced glycation end products (AGEs) may induce cardiac remodeling in kidney disease by promoting fibroblast growth factor 23 (FGF-23) expression.
|
29147074 |
2017 |
|
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, high FGF23 levels become pathological as kidney disease progresses and are associated with an increased risk of CKD progression, cardiovascular events, and death.
|
27582104 |
2017 |
|
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Circulating FGF23 levels rise precipitously in patients with kidney disease and portend worse renal and cardiovascular outcomes.
|
28919046 |
2017 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
FGF-23 was slightly elevated, perhaps from kidney disease.
|
27005479 |
2016 |
|
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Through independent and combined effects on renal phosphorus and vitamin D metabolism, alterations in FGF23 and Klotho expression are essential for maintaining mineral homeostasis in kidney disease.
|
23611556 |
2013 |
|
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We investigated the association between FGF23 serum levels and kidney disease progression, as well as the phenotypic features of CKD-MBD in a Col4a3 null mouse model of human autosomal-recessive Alport syndrome.
|
22031097 |
2012 |
|
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Regulation of fibroblast growth factor-23 in chronic kidney disease.
|
17567652 |
2007 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
LHGDN |
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
|
14633152 |
2003 |